Rhonda L Bitting1, Patrick Healy2, Patricia A Creel1, James Turnbull1, Karla Morris1, Sarah Yenser Wood3, Herbert I Hurwitz4, Mark D Starr3, Andrew B Nixon4, Andrew J Armstrong5, Daniel J George6. 1. Duke Cancer Institute, Duke University Medical Center, Durham, NC. 2. Department of Biostatistics and Bioinformatics, Duke University Medical Center, Durham, NC. 3. Division of Medical Oncology, Department of Medicine, Duke University Medical Center, Durham, NC. 4. Division of Medical Oncology, Department of Medicine, Duke University Medical Center, Durham, NC; Duke Cancer Institute, Duke University Medical Center, Durham, NC. 5. Division of Medical Oncology, Department of Medicine, Duke University Medical Center, Durham, NC; Division of Urology, Department of Surgery, Duke University Medical Center, Durham, NC; Duke Cancer Institute, Duke University Medical Center, Durham, NC. 6. Division of Urology, Department of Surgery, Duke University Medical Center, Durham, NC; Duke Cancer Institute, Duke University Medical Center, Durham, NC. Electronic address: daniel.george@duke.edu.
Abstract
BACKGROUND: Vatalanib is an oral vascular endothelial growth factor receptor (VEGFR) tyrosine kinase inhibitor (TKI), whereas everolimus inhibits mammalian target of rapamycin (mTOR). Combination therapy with VEGFR and mTOR inhibitors has not been well tolerated to date but may have efficacy in renal cell carcinoma (RCC). PATIENTS AND METHODS: A phase Ib study of vatalanib and everolimus was performed in patients with advanced solid tumors to determine the maximum tolerated dose (MTD), safety, and tolerability of the combination. A dose-expansion cohort of 20 patients with metastatic RCC was studied to further define toxicity and preliminary efficacy in patients with RCC. RESULTS: We evaluated 32 patients over 3 dose levels and a dose-expansion cohort. The most common toxicities of any grade were proteinuria, fatigue, hypertriglyceridemia, nausea, and vomiting. Dose-limiting toxicities (DLTs) included severe hypertension, diarrhea, neutropenia, mucositis, and fatigue. The MTD for the combination was vatalanib 1000 mg daily and everolimus 5 mg daily. In all patients, median overall survival (OS) was 16.3 months. In patients with RCC, median progression-free survival (PFS) was 5.8 months, and OS was 16.5 months. OS was significantly better in treatment-naive patients (25.1 months) compared with patients who had received previous vascular endothelial growth factor (VEGF)-targeted therapy (6.3 months). Seven of 24 (29.2%) evaluable patients demonstrated a partial response, and an additional 15 patients exhibited stable disease. Long-term tolerability (> 1 year) was demonstrated in 19% of patients. CONCLUSION: Relevant doses of vatalanib and everolimus were achieved in combination, with expected toxicities. A substantial number of patients with RCC achieved an objective response in the treatment-naive setting, with prolonged tolerability and survival. Further comparative phase II/III studies of specifically targeted VEGF and mTOR inhibitor combinations may be warranted in patients with RCC.
BACKGROUND:Vatalanib is an oral vascular endothelial growth factor receptor (VEGFR) tyrosine kinase inhibitor (TKI), whereas everolimus inhibits mammalian target of rapamycin (mTOR). Combination therapy with VEGFR and mTOR inhibitors has not been well tolerated to date but may have efficacy in renal cell carcinoma (RCC). PATIENTS AND METHODS: A phase Ib study of vatalanib and everolimus was performed in patients with advanced solid tumors to determine the maximum tolerated dose (MTD), safety, and tolerability of the combination. A dose-expansion cohort of 20 patients with metastatic RCC was studied to further define toxicity and preliminary efficacy in patients with RCC. RESULTS: We evaluated 32 patients over 3 dose levels and a dose-expansion cohort. The most common toxicities of any grade were proteinuria, fatigue, hypertriglyceridemia, nausea, and vomiting. Dose-limiting toxicities (DLTs) included severe hypertension, diarrhea, neutropenia, mucositis, and fatigue. The MTD for the combination was vatalanib 1000 mg daily and everolimus 5 mg daily. In all patients, median overall survival (OS) was 16.3 months. In patients with RCC, median progression-free survival (PFS) was 5.8 months, and OS was 16.5 months. OS was significantly better in treatment-naive patients (25.1 months) compared with patients who had received previous vascular endothelial growth factor (VEGF)-targeted therapy (6.3 months). Seven of 24 (29.2%) evaluable patients demonstrated a partial response, and an additional 15 patients exhibited stable disease. Long-term tolerability (> 1 year) was demonstrated in 19% of patients. CONCLUSION: Relevant doses of vatalanib and everolimus were achieved in combination, with expected toxicities. A substantial number of patients with RCC achieved an objective response in the treatment-naive setting, with prolonged tolerability and survival. Further comparative phase II/III studies of specifically targeted VEGF and mTOR inhibitor combinations may be warranted in patients with RCC.
Authors: Andrew J Armstrong; George J Netto; Michelle A Rudek; Susan Halabi; David P Wood; Patricia A Creel; Kelly Mundy; S Lindsay Davis; Ting Wang; Roula Albadine; Luciana Schultz; Alan W Partin; Antonio Jimeno; Helen Fedor; Phillip G Febbo; Daniel J George; Robin Gurganus; Angelo M De Marzo; Michael A Carducci Journal: Clin Cancer Res Date: 2010-05-25 Impact factor: 12.531
Authors: Darcy A Krueger; Marguerite M Care; Katherine Holland; Karen Agricola; Cynthia Tudor; Prajakta Mangeshkar; Kimberly A Wilson; Anna Byars; Tarek Sahmoud; David Neal Franz Journal: N Engl J Med Date: 2010-11-04 Impact factor: 91.245
Authors: David Spigel; Suzanne Jones; John Hainsworth; Jeff Infante; F Anthony Greco; Dana Thompson; Habib Doss; Howard Burris Journal: Cancer Invest Date: 2011-05 Impact factor: 2.176
Authors: J Randolph Hecht; Tanja Trarbach; John D Hainsworth; Pierre Major; Elke Jäger; Robert A Wolff; Katherine Lloyd-Salvant; György Bodoky; Kelly Pendergrass; William Berg; Bee-Lian Chen; Tarja Jalava; Gerold Meinhardt; Dirk Laurent; David Lebwohl; David Kerr Journal: J Clin Oncol Date: 2011-04-04 Impact factor: 44.544
Authors: Eric Van Cutsem; Emilio Bajetta; Juan Valle; Claus-Henning Köhne; J Randolph Hecht; Malcolm Moore; Colin Germond; William Berg; Bee-Lian Chen; Tarja Jalava; David Lebwohl; Gerold Meinhardt; Dirk Laurent; Edward Lin Journal: J Clin Oncol Date: 2011-04-04 Impact factor: 44.544
Authors: James C Yao; Manisha H Shah; Tetsuhide Ito; Catherine Lombard Bohas; Edward M Wolin; Eric Van Cutsem; Timothy J Hobday; Takuji Okusaka; Jaume Capdevila; Elisabeth G E de Vries; Paola Tomassetti; Marianne E Pavel; Sakina Hoosen; Tomas Haas; Jeremie Lincy; David Lebwohl; Kjell Öberg Journal: N Engl J Med Date: 2011-02-10 Impact factor: 91.245
Authors: Terence O'Reilly; Heidi A Lane; Jeanette M Wood; Christian Schnell; Amanda Littlewood-Evans; Josef Brueggen; Paul M J McSheehy Journal: Cancer Chemother Pharmacol Date: 2010-05-30 Impact factor: 3.333
Authors: Axel Grothey; Eric Van Cutsem; Alberto Sobrero; Salvatore Siena; Alfredo Falcone; Marc Ychou; Yves Humblet; Olivier Bouché; Laurent Mineur; Carlo Barone; Antoine Adenis; Josep Tabernero; Takayuki Yoshino; Heinz-Josef Lenz; Richard M Goldberg; Daniel J Sargent; Frank Cihon; Lisa Cupit; Andrea Wagner; Dirk Laurent Journal: Lancet Date: 2012-11-22 Impact factor: 79.321
Authors: Michael I Koukourakis; Alexandra Giatromanolaki; Efthimios Sivridis; Kevin C Gatter; Tanja Trarbach; Gunnar Folprecht; Michael M Shi; David Lebwohl; Tarja Jalava; Dirk Laurent; Gerold Meinhardt; Adrian L Harris Journal: Clin Cancer Res Date: 2011-06-01 Impact factor: 12.531
Authors: Katrina S Pedersen; Patrick M Grierson; Joel Picus; A Craig Lockhart; Bruce J Roth; Jingxia Liu; Ashley Morton; Emily Chan; Jesse Huffman; Chris Liang; Andrea Wang-Gillam; Benjamin Tan Journal: Invest New Drugs Date: 2021-03-18 Impact factor: 3.850
Authors: Mathias Alrø Fichtner Bendtsen; Daniela Grimm; Johann Bauer; Markus Wehland; Petra Wise; Nils E Magnusson; Manfred Infanger; Marcus Krüger Journal: Int J Mol Sci Date: 2017-08-10 Impact factor: 5.923
Authors: Johanna C Bendell; Robin K Kelley; Kent C Shih; Jennifer A Grabowsky; Emily Bergsland; Suzanne Jones; Thomas Martin; Jeffrey R Infante; Paul S Mischel; Tomoo Matsutani; Shuichan Xu; Lilly Wong; Yong Liu; Xiaoling Wu; Deborah S Mortensen; Rajesh Chopra; Kristen Hege; Pamela N Munster Journal: Cancer Date: 2015-07-15 Impact factor: 6.921